A Randomized, Open-Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetael to Dostarlimab + Docetael to Docetael Alone In Participants with Advanced Nonsmall Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy (COSTAR Lung)
This research study is being done to test combinations of study drugs to treat lung cancer and see if they work better than the single drug docetaxel. Two of the drugs in this study (dostarlimab and cobolimab) are experimental which means they have not been fully tested yet and are not yet approved to treat any disease. The other drug in this study, docetaxel, is already approved by the United States Food and Drug Administration (FDA) and is a common treatment for patients with lung cancer.
This is a multicenter, parallel-group treatment, Phase 2/3 open-label, 3-arm study comparing cobolimab + dostarlimab + docetael to dostarlimab + ocetael to docetael alone for efficacy in male and female participants aged 18 years and older with advanced NSCLC who have progressed on prior anti-PD-(L)1 therapy and chemotherapy.
-Advanced or metastatic NSCLC, including squamous or non-squamous cell carcinoma.
-Received no more than 2 prior lines of therapy, which must include a platinum based chemotherapy (e.g., cisplatin, carboplatin) and an anti-PD-(L)1 antibody.
-Participant has measurable disease.
-Documented radiographic disease progression on prior platinum based chemotherapy and on or after prior anti-PD-(L)1 therapy.
Let us know how the study team can reach you. If you do not hear back within 2 business days, reach out to the study team directly at the
contact information above or email email@example.com and someone will assist you.
Your information will be shared only with the research study team for recruitment purposes and designated CTSI personnel for project quality
assurance and will remain confidential. Your information will be stored indefinitely. Should you no longer want this information to be provided
in the aforementioned ways, please contact firstname.lastname@example.org.